Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors
Menée à partir de données portant sur 88 patients présentant une tumeur pulmonaire ultra-centrale (âge médian : 74 ans), cette étude analyse la toxicité des agents anti-angiogéniques en combinaison avec une radiothérapie corporelle stéréotaxique
Lung stereotactic body radiation therapy (SBRT) is an effective and generally safe treatment for lung cancer, but a higher rate of toxic effects has been reported for SBRT within the central lung zone.1 Patients receiving SBRT for tumors abutting the proximal bronchial tree (PBT) or esophagus, known as “ultracentral” tumors, may have a particularly high risk of toxic effects.2 Antiangiogenic agents (AAAs) have been suspected to potentiate SBRT toxic effects in other body sites.3 Herein, we report on the toxic effects associated with SBRT for ultracentral lung tumors, with a focus on exposure to AAAs.